ANAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Given the neutral technical indicators, lack of recent positive trading signals, mixed financial performance, and absence of significant catalysts or news, AnaptysBio Inc (ANAB) does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. Holding or waiting for clearer signals is recommended.
The MACD is positive but contracting, RSI is neutral at 54.688, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are Pivot: 65.115, R1: 71.712, S1: 58.518. The stock is trading near its pivot point, indicating indecision in the market.
Analysts have raised price targets significantly, with Piper Sandler and UBS projecting $95 and $90 respectively, citing strong pipeline potential and JEMPERLI's success. The planned Q2 spin-off of the biopharma portfolio could unlock value.
The stock has declined in pre-market (-0.18%), regular market (-1.46%), and post-market (-1.93%) trading. Financial performance shows a significant drop in net income (-327.75% YoY) and EPS (-348.61% YoY), despite revenue growth. No recent news or congress trading data to act as a positive catalyst.
In Q4 2025, revenue increased by 151.08% YoY to $108.25M, driven by JEMPERLI milestones. However, net income dropped by -327.75% YoY to $49.61M, and EPS fell by -348.61% YoY to 1.79, indicating profitability challenges.
Analysts are generally bullish, with multiple firms raising price targets (e.g., Piper Sandler to $95, UBS to $90, Stifel to $85). However, Truist maintains a Hold rating due to pipeline concerns and legal overhang.
